Abstract
The course of contact dermatitis is variable: the condition may resolve, or recur in the same site, or else spread and become unpredictably chronic. Although rarely, it can be complicated by erythroderma, which is often irreversible, has a poor prognosis and can even be fatal. With the exception of the last complication, the prognosis of contact dermatitis in its various clinical expressions is favorable. The course of the disease can be stopped only if contact with the agent or agents responsible is avoided. Topical or systemic treatments are useful only to reduce the duration of the clinical episode. Topical treatment and in part, systemic treatment are largerly similar in the two different forms of irritant and allergic contact dermatitits. Local treatment relies on Galenic products (solutions or antiseptic tinctures, emulsions and soothing lotions, powders, pastes and creams), that must be used considering the clinical phase of the disease (acute, subacute, chronic) and the relative manifestations. Apart from these very useful products, topical corticosteroids can be used with some important criteria, such as time and modality of use. Systemic antihistamines can be used for short or long periods to calm the pruritus. Systemic corticosteroids are used only in forms that are highly refractory to other treatments, and in diffuse and erythrodermic forms. Various other physical (ultraviolet light, Grenz rays) and chemical (antimetabolites, such as methotrexate, azathioprine, mycophenolate mofetil; IFN-γ antagonists, such as cyclosporin, apremilast; TNF-α antagonists, such as infliximab, etanercept; IL-4 receptor-α antagonists, such as dupilumab; calcineurin inhibitors, such as tacrolimus and pimecrolimus) substances can be used as attempts of immunotolerance. Many attempts have been also provided to induce specific oral tolerance to nickel in nickel-allergic subjects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Meneghini CL, Angelini G. Le dermatiti da contatto. Roma: Lombardo Ed. Roma; 1982.
Bonamonte D, Cavani A, Angelini G. Allergic contact dematitis. In: Giannetti A, Del Forno C, editors. Textbook of dermatology and sexually transmitted diseases. Padova: Piccin Nuova Libraria; 2013. p. 933.
Goh CL. Prognosis of occupational contact dermatitis. In: Kanerva L, Elsner P, Wahlberg JE, et al., editors. Handbook of occupational dermatology. Berlin: Springer; 2000. p. 444.
Chia SE, Goh CL. Prognosis of occupational dermatitis in Singapore Worker. Am J Contact Dermatitis. 1991;2:105.
Rosen RH, Freeman S. Prognosis of occupational contact dermatitis in New South Wales, Australia. Contact Dermatitis. 1993;29:88.
Nethercott J, Holness L. Disease outcome in workers with occupational skin disease. J Am Acad Dermatol. 1994;30:569.
Burrows D. Prognosis in industrial dermatitis. Br J Dermatol. 1972;87:145.
Fregert S. Occupational contact dermatitis in a 10-year material. Contact Dermatitis. 1975;1:96.
Avnstorp C. Follow-up of workers from the prefabricated concrete industry after the addition of ferrous sulphate to Danish cement. Contact Dermatitis. 1989;20:365.
Pryce DW, Irvine D, English JSC, et al. Soluble oil dermatitis: a follow-up study. Contact Dermatitis. 1989;21:28.
Shah M, Lewis FM, Gawkrodger DJ. Prognosis of occupational hand dermatitis in metalworkers. Contact Dermatitis. 1996;34:27.
Christensen OB. Prognosis in nickel allergy and hand eczema. Contact Dermatitis. 1982;8:7.
Rystedt I. Hand eczema and long-term prognosis in atopic dermatitis. Acta Derm Venereol. 1985;117(Suppl):1.
Matsunaga K, Hosokawa K, Suzuki M, et al. Occupational allergic contact dermatitis in beauticians. Contact Dermatitis. 1998;18:94.
Halbert AR, Gebauer KA, Wall LM. Prognosis of occupational chromate dermatitis. Contact Dermatitis. 1993;27:214.
Angelini G, Vena GA. Gestione e terapia della dermatite da contatto. In: Angelini G, Vena GA. editors. Dermatologia professionale e ambientale, vol III. Brescia: ISED;1999. p. 825.
Sadhra S. Dermatitis: identifying the culpit. Occup Health. 1987;3:222.
Angelini G, Vena GA. Il dermatologo è il clinico meglio qualificato per l’esecuzione dei patch tests. Giorn Ital Dermatol Venereol. 1995;130:85.
Rycroft RJG. Looking at work dermatologically. Dermatol Clin. 1988;6:1.
Barry BW. Dermatological formulations. Percutaneous absorption. New York: Marcel Dekker; 1983.
Angelini G, Foti C, Vena GA. Terapia farmacologica delle dermatiti allergiche. In: Paoletti R, Nicosia S, Clementi F, et al., editors. Trattato di farmacologia e terapia. UTET, Torino: Dermofarmacologia; 1998. p. 157.
Vena GA, Foti C, Piazzolla E, et al. Can cyclosporin A help to distinguish allergic from irritant patch test reactions? Contact Dermatitis. 1994;31:256.
Toews GB, Bergstresser PR, Strellein JW. Epidermal Langerhans cell density determines whether contact sensitivity or unresponsiveness following skin painting with DNFB. J Immunol. 1980;124:445.
Elmets CA, Bergstresser PR, Tigelar RE, et al. Analysis of the mechanism of unresponsiveness produced by haptens painted on skin exposed to low dose of ultraviolet radiation. J Exp Med. 1983;158:781.
Baer H, Hooton ML, Dawson CR, et al. The induction of immune tolerance in delayed contact sensitivity by the use of chemically related substances of low immunogenicity. J Invest Dermatol. 1977;69:215.
Sommer G, Parker D, Turk JL. Epicutaneos induction of hyporeactivity in contact sensitization: demonstration of suppressor cells induced by contact with 2,4-dinitrothyocyanatebenzene. Immunology. 1975;29:517.
Jijima M, Katz SI. Specific tolerance to dinitrofluorobenzene following topical application of dinitrocyanobenzene. J Invest Dermatol. 1983;81:325.
Bergstresser PR. Immune mechanism in contact allergic dermatitis. Dermatol Clin. 1990;8:3.
Stingl LA, Sauber DN, Jijima M, et al. Mechanism of UVB-induced impairment of the antigen-presenting capacity of murine epidermal cells. J Immunol. 1983;130:1586.
Rae V, Yoshikawa T, Streilein JW, et al. Unresponsiveness induced in man by DNCB painted on UVB-treated skin. Clin Res. 1989;37:685A.
Streilein JW, Bergstresser PR. Genetic factors in ultraviolet-B suppression of contact hypersensitivity in mice. Immunogenetics. 1988;27:252.
Hamau D, Fabre M, Lepoittevin J-P, et al. ATPase and morphologic changes induced by UVB on Langerhans cells in guinea pig. J Invest Dermatol. 1985;85:135.
Rappersberger K, Gartner S, Schenk P. Langerhans cells are an actual site of HIV-1 replication. Intervirology. 1988;29:185.
Monti M, Zerboni S, Cusini. Evaluation of experimental induced DNCB hypersensitivity in human immune deficiency virus (HIV) infected patients. Boll Dermatol Allergol Profes. 1987;2:235.
Meneghini CL, Angelini G. Behaviour of contact allergy and new sensitivities on subsequent patch tests. Contact Dermatitis. 1977;3:138.
Valsecchi R, Rossi A, Bigardi A, et al. The loss of contact sensitization in man. Contact Dermatitis. 1991;24:183.
Vena GA, Foti C, Angelini G. Studio sulle variazioni nel tempo delle sensibilizzazioni da contatto. Boll Dermatol Allergol Profes. 1992;7:247.
Bourke J, Coulson I, English J. Guidelines for the management of contact dermatitis: an update. Br J Dermatol. 2009;160:946.
Zhai H, Anigbogu A, Maibach HI. Treatment of irritant and allergic contact dermatitis. In: Kanerva L, Elsner P, Wahlberg JE, et al., editors. Handbook of occupational dermatitis. Berlin: Springer; 2000. p. 402.
Cohen DE, Heidary N. Treatment of irritant and allergic contact dermatitis. Dermatol Ther. 2004;17:334.
Sung CT, Mc Gowan MA, Machler BC, et al. Systemic treatment for allergic contact dermatitis. Dermatitis. 2019;30:46.
Brasch J, Becker B, Aberer W, et al. Guideline contact dermatitis. Allergy J Int. 2014;23:126.
Warshaw E, Lee G, Storrs FJ. Hand dermatitis: a review of clinical features, therapeutic options, and longterm outcomes. Am J Contact Dermatitis. 2003;14:119.
Mork NJ, Austad J. Short-wave ultraviolet light (UVB) treatment of allergic contact dermatitis of the hands. Acta Derm Venereol. 1983;63:87.
Sjövall P, Christensen OB. Local and systemic effect of ultraviolet irradiation (UVA and UVB) on human allergic contact dermatitis. Acta Derm Venereol. 1986;66:290.
Sjövall P, Christensen OB. Treatment of chronic hand eczema with UV-B Handylux in the clinic and at home. Contact Dermatitis. 1994;31:5.
Stege H. Ultraviolet-therapic des chronischen Handekzems. Hautarzt. 2008;59:696.
Rosen K, Mobacken H, Swanbeck G. Chronic eczematous dermatitis of the hands: a comparison of PUVA and UVB treatment. Acta Derm Venereol. 1987;67:48.
Simons JR, Bohnen JJ, van der Walk PG. A left-right comparison of UVB phototherapy and topical photochemotherapy in bilateral chronic hand dermatitis after six weeks’ treatment. Clin Exp Dermatol. 1997;22:7.
Bauer A, Kelterer D, Bartsch R, et al. Prevention of hand dermatitis in bakers’ apprentices: different efficacy of skin protection measures and UVB hardening. Int Arch Occup Environ Health. 2002;75:491.
Schmidt T, Abeck D, Boeck K, et al. UVA1 irradiation is effective in treatment of chronic vesicular dyshidrotic hand eczema. Acta Derm Venereol. 1998;78:318.
Petering H, Breuer C, Herbst R, et al. Comparison of localized high-dose UVA 1 irradiation versus topical cream psoralen. UVA for treatment of chronic vesicular dyshidrotic eczema. J Am Acad Dermatol. 2004;50:68.
Sezer E, Etikan I. Local narrow-band UVB phototherapy vs local PUVA in the treatment of chronic hand eczema. Photodermatol Photoimmunol Photomed. 2007;23:10.
Lindel L. The duration of Grenz ray-induced suppression of allergic contact dermatitis and its correlation with the density of Langerhans cells in human epidermis. Clin Exp Dermatol. 1989;14:206.
King CM, Chalmers RJG. A double-blind study of superficial radiotherapy in chronic palmar eczema. Br J Dermatol. 1984;111:445.
Linderöf B, Wrangsjö K, Lidén S. A double-blind study of Grenz ray therapy in chronic eczema of the hands. Br J Dermatol. 1987;117:77.
Schalok PC, Zug KA, Carter JC, et al. Efficacy and patient perception of Granz ray therapy in the treatment of dermatoses refractory to other medical therapy. Dermatitis. 2008;19:90.
Warner JA, Cruz PD Jr. Grenz ray therapy in the new millennium: still a valid treatment option? Dermatitis. 2008;19:73.
Sheary B. Steroid withdrawal effects following long-term topical corticosteroid use. Dermatitis. 2018;29:213.
Olupana T, Scheinman P. Successful patch testing despite concomitant low-dose prednisone use. Dermatitis. 2008;19:117.
Anveden I, Lindberg M, Cudersen KE, et al. Oral prednisone suppresses allergic but not irritant patch test reactions in individuals hypersensitive to nickel. Contact Dermatitis. 2004;50:298.
Feuerman E, Levy A. A study of the effect of prednisone and an antihistamine on patch test reactions. Br J Dermatol. 1972;86:68.
Hachem JP, De Paepe K, Vanpée E, et al. Efficacy of topical corticosteroids in nickel-induced contact allergy. Clin Exp Dermatol. 2002;27:47.
Queille-Roussel C, Duteil L, Padilla J-M, et al. Objective assessment of topical anti-inflammatory drug activity on experimentally induced nickel contact dermatitis: comparison between visual scoring, colorimetry, laser Doppler velocimetry, and transepidermal water loss. Skin Pharmacol. 1990;3:248.
Le TK, De Mon P, Schalkwijk J, et al. Effect of a topical corticosteroid, a retinoid and vitamin D3 derivative on sodium dodecyl sulphate-induced skin irritation. Contact Dermatitis. 1997;37:19.
Levin C, Zhai H, Bashir S, et al. Efficacy of corticosteroids in acute experimental irritant contact dermatitis. Skin Res Technol. 2001;7:214.
Tian H, Croustein BN. Understandind the mechanisms of action of methotrexate: inplications for the treatment of rheumatoid arthritis. Bull NYU Hosp J Dis. 2007;65:168.
Jeffes EW, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995;104:183.
Patel A, Burns E, Burkemper NM. Methotrexate use in allergic contact dermatitis: a retrospective study. Contact Dermatitis. 2018;78:194.
Sharma VK, Chakrabarti A, Mahajan V. Azathioprine in the treatment of Parthenium dermatitis. Int J Dermatol. 1998;37:299.
Verma KK, Bansal A, Sethuraman G. Parthenium dermatitis treated with azathioprine weekly pulse doses. Indian J Dermatol Venereol Leprol. 2006;72:24.
Agarwal US, Besarwal RK. Topical clobetasol propionate 0.05% cream alone and in combination with azathioprine in patients with chronic hand eczema: an observer blinded randomized comparative trial. Indian J Dermatol Venereol Leprol. 2013;79:101.
Verma KK, Mahesh R, Srivastava P, et al. Azathioprine versus betamethasone for the treatment of Parthenium dermatitis: a randomized controlled study. Indian J Dermatol Venereol Leprol. 2008;74:453.
Kaushal K, Manchanda Y. Long-term safety and toxicity of azathioprine in patients with airborne contact dermatitis. Indian J Dermatol Venereol Leprol. 2001;67:75.
Oosterhaven JA, Politiek K, Schuttelaar MA. Azathioprine treatment and drug survival in patients with chronic hand eczema—results from daily practice. Contact Dermatitis. 2017;76:304.
Amnuaikit T, Songkram C, Pinsuwan S. Enhancement of mycophenolate mofetil permeation for topical use by eucalyptol and N-methyl-2-pyrrolidone. Scientifica (Cairo). 2016;9672718.
Nguyen RH, Cruz PD Jr. Hepatitis due to mycophenolate mofetil used to treat atopic dermatitis and allergic contact dermatitis. Dermatitis. 2014;25:284.
Fallahi P, Ruffilli I. Contact dermatitis and interferon-gamma dependent chemockines. Clin Ther. 2016;167:e 112.
Bordignon V, Palamara F, Cordiali-Fei P, et al. Nickel, palladium and rhodium induced IFN-gamma and IL-10 production as assessed by in vitro ELISpot- analysis in contact dermatitis patients. BMC Immunol. 2008;9:19.
Forsbeck M, Hovmark A, Skog E. Patch testing, tuberculin testing and sensitization with dinitrochlorobenzene and nitrosodimethylaniline of patients with atopic dermatitis. Acta Derm Venereol. 1976;56:135.
Cooper KD, Voorhees JJ, Fisher GJ, et al. Effects of cyclosporin on immunologic mechanism in psoriasis. J Am Acad Dermatol. 1990;23:1318.
Pubchem. Cyclosporine. 2018. http://www.ncbi.nlm.nih.gov/pubmed/.
Dupuy P, Bagot M, Michel L, et al. Cyclosporin inhibits antigen-presenting functions of freshly isolated human Langerhans cells. J Invest Dermatol. 1991;96:408.
Higgins EM, McLelland J, Friedmann PS, et al. Oral cyclosporine inhibits the expression of contact hypersensitivity in man. J Dermatol Sci. 1991;2:79.
Vena GA, Foti C, Grandolfo M, et al. Trattamento della dermatite da contatto con ciclosporina A. Boll Dermatol Allergol Profes. 1993;2:275.
Gronlund H, Erkko P, Eriksson E, et al. Comparison of cyclosporine and topical betamethasone-17,21-dipropionate in the treatment of severe chronic hand eczema. Acta Derm Venereol. 1996;76:371.
Prignano F, Bonciolini V, Bonciani D, et al. Exacerbation of allergic contact dermatitis during immunosuppression with cyclosporine A. Giorn Ital Dermatol Venereol. 2010;145:543.
Kundu RV, Scheman AJ, Gutmanovich A, et al. Contact dermatitis to white petrolatum. Skinmed. 2004;3:295.
Abrouk M, Farahnik B, Zhu TH, et al. Apremilast treatment of atopic dermatitis and other chronic eczematous dermatoses. J Am Acad Dermatol. 2017;77:177.
West CE, Fowler JF. Clearance of erythroderma in a patient on apremilast and positive patch test reactions while on treatment. Dermatitis. 2016;27:392.
Volf EM, Au SC, Dumont N, et al. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol. 2012;11:341.
Dittmar D, Schuttelaar ML. Immunology and genetics of tumor necrosis factor in allergic contact dermatitis. Contact Dermatitis. 2017;76:257.
Cumberbatch M, Kimber I. Tumor necrosis factor-alpha is required for accumulation of dendritic cells in draining limph nodes and for optimal contact sensitization. Immunology. 1995;84:31.
Westphal GA, Schnuch A, Moessner R, et al. Cytokine gene polymorphisms in allergic contact dermatitis. Contact Dermatitis. 2003;48:93.
Kaplan DH, Igyarto BZ, Gaspari AA. Early immune events in the induction of allergic contact dermatitis. Nat Rev Immunol. 2012;12:114.
Wee JS, White JM, McFadden JP, et al. Patch tests in patients treated with systemic immunosuppression and cytokine inhibitors. Contact Dermatitis. 2010;62:165.
Kim N, Notik S, Gottlieb AB, et al. Patch test results in psoriasis patients on biologics. Dermatitis. 2014;25:182.
Cassano N, Loconsole F, Coviello C, et al. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int J Immunopathol Pharmacol. 2006;19:237.
Rosmarin D, Bush M, Scheinman PL. Patch testing a patient with allergic contact hand dermatitis who is taking infliximab. J Am Acad Dermatol. 2008;59:145.
Conner E, Bochner BS, Brummet M, et al. The effect of etanercept an the human cutaneous allergic response. J Allergy Clin Immunol. 2008;121:258.
Horohov DW, Crim JA, Smith PL, et al. IL-4 (B-cell stimulatory factor 1) regulates multiple aspects of influenza virus-specific cell-mediated immunity. J Immunol. 1988;141:4217.
Koga T, Fujimura T, Imayama S, et al. The expression of Th1 and Th2 type cytokines in a lesion of allergic contact dermatitis. Contact Dermatitis. 1996;35:105.
Niiyama S, Tamauchi H, Amoh Y, et al. Th2 immune response plays a critical role in the development of nickel-induced allergic contact dermatitis. Int Arch Allergy Immunol. 2010;153:303.
Joshi SR, Khan DA. Effective use of dupilumab in managing systemic allergic contact dermatitis. Dermatitis. 2018;39:282.
Rowe A, Bunker CB. Interleukin-4 and the interleukin-4 receptor in allergic contact dermatitis. Contact Dermatitis. 1998;38:36.
Salerno A, Dieli F, Sireci G, et al. Interleukin-4 is a critical cytokine in contact sensitivity. Immunology. 1999;84:404.
Yokozeki H, Watanabe K, Igawa K, et al. Gammadelta T cells assist alphabeta T cells in the adaptive transfer of contact hypersensitivity to paraphenylenediamine. Clin Exp Immunol. 2001;125:351.
Puza CJ, Atwater AR. Positive patch test reaction in a patient taking dupilumab. Dermatitis. 2018;29:89.
Machler BC, Sung CT, Darwin E, et al. Dupilumab use in allergic contact dermatitis. J Am Acad Dermatol. 2018;80:280.
Goldminz AM, Scheinman PL. A case series of dupilumab-treated allergic contact dermatitis patients. Dermatol Ther. 2018;24:e12701.
Hoot JW, Douglas JD, Falo LD Jr. Patch testing in a patient on dupilumab. Dermatitis. 2018;29:164.
Chipalkatti N, Zancanaro P, Rosmarin D. Dupilumab as a treatment for allergic contact dermatitis. Dermatitis. 2018;29:347.
Bornhövd E, Burgdorf WH, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin diseases. J Am Acad Dermatol. 2001;45:736.
Saripalli YV, Gadzia J, Belsito D. Tacrolimus ointment 0.1% in the treatment of nickel-induced allergic contact dermatitis. J Am Acad Dermatol. 2003;49:477.
Gupta AK, Chow M. Pimecrolimus: a review. JEADV. 2003;17:493.
Amrol D, Keitel D, Hagaman D, et al. Topical pimecrolimus in the treatment of human allergic contact dermatitis. Ann Allergy Asthma Immunol. 2003;91:563.
Alomar A, Puig L, Gallardo CM, et al. Topical tacrolimus 0.1% ointment (protopic) reverses nickel contact dermatitis elicited by allergen challenge to a similar degree to momethasone furoate 0.1% with greater suppression of late erythema. Contact Dermatitis. 2003;49:185.
Queille-Roussel C, Graeber M, Thurston M, et al. SDZ ASM 981 is the first non-steroid that suppresses established nickel contact dermatitis elicited by allergen challenge. Contact Dermatitis. 2000;42:349.
Krejci-Manwaring J, McCarthy MA, Camacho F, et al. Topical tacrolimus 0.1% improves symptoms of hand dermatitis in patients treated with a prednisone taper. J Drugs Dermatol. 2008;7:643.
Aschoff R, Schmitt J, Knuschke P, et al. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20:832.
Rietschel RL, Fowler JF Jr. Treatment of contact dermatitis. In: Rietschel RL, Fowler JF Jr, editors. Fisher’s contact dermatitis. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 715.
Eberting CL, Blickenstaff N, Goldenberg A. Pathophysiologic treatment approach to irritant contact dermatitis. Curr Treat Options Allergy. 2014;1:317.
Lachapelle JM, Gimenez-Arnau A, Metz M, et al. Best practices, new perspectives and the perfect emollient: optimizing the management of contact dermatitis. J Dermatolog Treat. 2018;29:241.
Lodén M. Barrier recovery and influence of irritant stimuli in skin treated with a moisturizing cream. Contact Dermatitis. 1997;36:256.
Zhai H, Maibach HI. Moisturizers in preventing irritant contact dermatitis: an overview. Contact Dermatitis. 1998;38:241.
Lynde CW. Moisturizers: what they are and how they work. Skin Therapy Lett. 2001;6:3.
Lodén M. Role of topical emollients and moisturizers in the treatment of dray skin barrier disorders. Am J Clin Dermatol. 2003;4:771.
Cork MJ. The importance of skin barrier function. J Dermatol Treatm. 1997;8:57.
Zhai H, Maibach HI. Barriers creams-skin protectants: can you protect skin? J Cosmetic Dermatol. 2002;1:20.
Sympson EL, Chalmers JR, Hanifin JM, et al. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. J Allergy Clin Immunol. 2014;134:818.
Schwensen JF, Früs VF, Menné T, et al. One thousand cases of severe occupational contact dermatitis. Contact Dermatitis. 2013;68:259.
Hines J, Wilkinson SM, John SM, et al. The three moments of skin creams in the prevention of irritant contact dermatitis in the workplace. JEADV. 2017;31:53.
Lachapelle JM. Airborne irritant dermatitis. In: Chew A-L, Maibach HI, editors. Irritant dermatitis. Berlin, New York: Springer; 2006. p. 71.
Meding B, Jarvholm B. Hand eczema in Swedish adult changes in prevalence between 1983 and 1996. J Invest Dermatol. 2002;118:719.
Meding B, Jarvholm B. Incidence of hand eczema—a population-based retrospective study. J Invest Dermaol. 2004;122:873.
Apfelbacher CJ, Radulescu M, Diepgen TL, et al. Occurrence and prognosis of hand eczema in the car industry: results from the PACO follow-up study (PACO II). Contact Dermatitis. 2008;58:322.
Diepgen TL, Coenraads PJ. The epidemiology of occupational contact dermatitis. Int Arch Occup Environ Health. 1999;72:496.
Thyssen JPJJ, Linneberg A, Menné T. The epidemiology of hand eczema in general population—prevalence and main findings. Contact Dermatitis. 2010;62:75.
Meding B, Lantto R, Lindahl G, et al. Occupational skin disease in Sweden—a 12-year follow-up. Contact Dermatitis. 2005;53:308.
Hald M, Berg ND, Elberling J, et al. Medical consultations in relation to severity of hand eczema in the general population. Br J Dermatol. 2008;158:773.
Londow K. Hand dermatitis. The perennial scourge. Postgrad Med. 1998;8:151.
Holden CA, Berth-Jones J. Eczema, lichenification, prurigo and erythroderma. In: Burns T, Breathnach SM, Cox N, et al., editors. Rook’s textbook of dermatology, 7th ed. Oxford: Blackwell Scientific Publications;2004. p 17.1.
Meding B, Wrangsjo K, Jarvholm B. Fifteen-year follow-up of hand eczema: persistence and consequences. Br J Dermatol. 2005;152:975.
Augustin M, Kussner D, Purwins, et al. Cost-of-illness of patients with chronic hand eczema in routine care: results from a multicentre study in Germany. Br J Dermatol. 2011;165:845.
Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70:158.
Scalone L, Cortesi PA, Mantovani LG, et al. Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: results from Italy. Br J Dermatol. 2014;172:187.
Thyssen JP, Johansen JD, Carlsen BC, et al. Prevalence of nickel and contact allergy among female patients with dermatitis before and after Danish government regulation: a 23-year retrospective study. J Am Acad Dermatol. 2009;61:799.
Marks JG Jr, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch-test results, 1998 to 2000. Am J Contact Dermatitis. 2003;14:59.
The European Surveillance System of Contact Allergies (ESSCA): results of patch testing the standard series, 2004. J Eur Acad Dermatol Venereol. 22:174.
Hostynek JJ. Nickel-induced hypersensitivity: etiology, immune reactions, prevention and therapy. Arch Dermatol Res. 2002;294:249.
Tsuji NM, Kosaka A. Oral tolerance: intestinal homeostasis and antigen-specific regulatory T cells. Trends Immunol. 2008;29:532.
Arnaboldi PM, Roth-Walter F, Mayer L. Suppression of Th1 and Th17, but not Th2, responses in a CD8 (+) T cell-mediated model of oral tolerance. Mucosal Immunol. 2009;2:427.
Artik S, Haarhuis K, Wu X, et al. Tolerance to nickel: oral nickel administration induces a high frequency of anergic T cells with persistent suppressor activity. J Immunol. 2001;167:6794.
Desvignes C, Bour H, Nicolas JF, et al. Lack of oral tolerance but oral priming for contact sensitivity to dinitrochlorobenzene in major histocompatibility complex class II- deficient mice and in CD4+ T cell-depleted mice. Eur J Immunol. 1996;26:1756.
Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy, and immunotherapy: implications for future treatment. J Allergy Clin Immunol. 2008;121:1344.
Dubois B, Chapat L, Goubier A, et al. Innate CD4+ CD25+ regulatory T cells are required for oral tolerance and inhibition of CD8+ T cells mediating skin inflammation. Blood. 2003;102:3295.
Faria AM, Weiner HL. Oral tolerance. Immunol Rev. 2005;206:232.
Chen Y, Inobe J, Weiner HL. Induction of tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression. J Immunol. 1995;155:910.
Chen Y, Inobe J, Marks R, et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 1995;376:177.
Chung Y, Chang WS, Kim S, et al. NKT cell ligand alpha-galactosylceramide blocks the induction of oral tolerance by triggering dendritic cell maturation. Eur J Immunol. 2004;34:2471.
Goubier A, Dubois B, Gheit H, et al. Plasmacytoid dendritic cells mediate oral tolerance. Immunity. 2008;29:464.
Cavani A, Nasorri F, Prezzi C, et al. Human CD4+ T lymphocytes with remarkable regulatory functions on dendritic cells and nickel-specific Th1 immune responses. J Invest Dermatol. 2000;114:295.
Cavani A, Nasorri F, Ottaviani C, et al. Human CD25+ regulatory cells maintain immunne tolerance to nickel in healthy, nonallergic individuals. J Immunol. 2003;171:5760.
Van Hoogstraoten IM, Andersen KE, Von Blomberg BM, et al. Reduced frequency of nickel allergy upon oral nickel contact at an early age. Clin Exp Immunol. 1991;85:441.
Mortz CG, Lauritsen JM, Bindslev-Jensen C, et al. Nickel sensitization in adolescents and association with ear piercing, use of dental braces and hand eczema. The Odense Adolescence Cohort Study on Atopic Disease and Dermatitis (TOACS). Acta Derm Venereol. 2002;82:359.
Bagot M, Terki N, Bacha S, et al. Per os desensitization in nickel contact eczema: a double-blind placebo-controlled clinic-biological study. Ann Dermatol Venereol. 1999;126:502.
Sjovall P, Christensen OB, Möller H. Oral hyposensitization in nickel allergy. J Am Acad Dermatol. 1987;17:774.
Morris DL. Intradermal tests and sublingual desensitization for nickel. Cutis. 1998;61:129.
Bonamonte D, Cristaudo A, Nasorri F, et al. Efficacy of oral hyposensitization in allergic contact dermatitis caused by nickel. Contact Dermatitis. 2011;65:293.
Bonamonte D, Guida S, Vestita M, et al. Allergic contact dermatitis to nickel: from clinical aspects to therapeutic measures. Clin Immunol Endocr Metabolic Drugs. 2014;1:75.
Veien NK, Hattel T, Laurberg G. Low nickel diet: an open, prospective trial. J Am Acad Dermatol. 1993;29:1002.
Antico A, Soana R. Chronic allergic-like dermatopathies in nickel-sensitive patients. Results of dietary restrictions and challenge with nickel salts. Allergy Asthma Proc. 1999;20:235.
Pizzutelli S. Systemic nickel hypersensitivity and diet: myth or reality? Eur Ann Allergy Clin Immunol. 2011;43:5.
Menné T, Kaaber K. Treatment of pompholyx due to nickel allergy with chelating agents. Contact Dermatitis. 1978;4:289.
Spruit D, Bongaarts PJM, De Jongh GJ. Dithiocarbamate therapy for nickel dermatitis. Contact Dermatitis. 1978;4:350.
Kaaber K, Menné T, Tjell JC, et al. Antabuse treatment of nickel dermatitis. Chelation- a new principle in the treatment of nickel dermatitis. Contact Dermatitis. 1979;5:221.
Christensen OB, Kristensen M. Treatment with disulfiram in chronic nickel hand dermatitis. Contact Dermatitis. 1982;8:59.
Kaaber K, Menné T, Veien NK, et al. Treatment of nickel dermatitis with Antabuse®; a double blind study. Contact Dermatitis. 1983;9:297.
Burrows D, Rogers S, Beck M, et al. Treatment of nickel dermatitis with trientine. Contact Dermatitis. 1986;15:55.
Kaaber K, Menné T, Veien NK, et al. Some adverse effects of disulfiram in the treatment of nickel-allergic patients. Dermatosen. 1987;35:209.
Sharma SC, Kaur S. Airborne contact dermatitis from Compositae plants in northern India. Contact Dermatitis. 1989;21:1.
Hausen BM. Parthenium hysterophorus allergy. A weed problem in India. Derm Beruf Umwelt. 1978;26:115.
Handa S, Sahoo B, Sharma VK. Oral hyposensitization in patients with contact dermatitis from Parthenium hysterophorus. Contact Dermatitis. 2001;44:279.
Bhutani LK, Rao DS. Photocontact dermatitis caused by Parthenium hysterophorus. Dermatologica. 1978;157:206.
Epstein WL, Bear H, Dawson CR, et al. Poison oak hyposensitization: evaluation of purified urushiol. Arch Dermatol. 1974;109:356.
Marks JG Jr, Trontlein JJ, Epstein WL, et al. Oral hyposensitization to poison ivy and poison oak. Arch Dermatol. 1987;123:476.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Bonamonte, D., Foti, C., Gullo, G., Angelini, G. (2021). Prognosis and Therapy. In: Angelini, G., Bonamonte, D., Foti, C. (eds) Clinical Contact Dermatitis. Springer, Cham. https://doi.org/10.1007/978-3-030-49332-5_26
Download citation
DOI: https://doi.org/10.1007/978-3-030-49332-5_26
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-49331-8
Online ISBN: 978-3-030-49332-5
eBook Packages: MedicineMedicine (R0)